Chugai and Takeda Collaborate to Evaluate the Combination Therapy for Multiple Tumor Types in Japan

 Chugai and Takeda Collaborate to Evaluate the Combination Therapy for Multiple Tumor Types in Japan

Chugai and Takeda Collaborate to Evaluate the Combination Therapy for Multiple Tumor Types in Japan

Shots:

  • Following a joint clinical research agreement between Roche and Exelixis and in conjunction with certain rights granted in Japan, Chugai and Takeda will study Tecentriq (atezolizumab) and Cabometyx (cabozantinib) as a combination therapy in Japan
  • The three global P- III CONTACT studies are ongoing to investigate the combination of atezolizumab and cabozantinib as a potential new treatment option in multiple tumor types, and Chugai and Takeda are planning to join in supporting P-III studies in Japan
  • Tecentriq is a mAb targeting PD-L1, acts by blocking is its interactions with both PD-1 and B7.1 receptor. Cabometyx is approved for advanced RCC and for HCC prior treated with sorafenib in the US

Click here ­to­ read full press release/ article | Ref: Chugai | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post